

Table S1 Laboratory findings of patients with COVID-19 during hospitalization

Characteristics	All patients (n=285)	Length of hospital stay			Complications		
		<18 days (n=131)	≥18 days (n=149)	P value	Yes (n=90)	No (n=195)	P value
At admission							
WBC, ×10 ⁹ /L	4.94 (3.99–6.31)	4.67 (3.90–6.00)	5.17 (4.11–6.53)	0.045	5.15 (3.90–6.53)	4.86 (4.00–6.24)	0.463
Neutrophil count, ×10 ⁹ /L	2.97 (2.14–4.00)	2.74 (2.05–3.60)	3.24 (2.19–4.40)	0.008	3.28 (2.08–4.66)	2.90 (2.15–3.89)	0.186
Monocytes, ×10 ⁹ /L	0.36 (0.29–0.58)	0.35 (0.28–0.44)	0.36 (0.29–0.48)	0.279	0.34 (0.27–0.41)	0.36 (0.30–0.47)	0.040
Haemoglobin, g/L	136 (123.5–146)	133.0 (121.0–145.0)	138.0 (125.0–146.0)	0.064	136.5 (125.5–145.5)	135.0 (123.0–146.0)	0.655
Lymphocyte count, ×10 ⁹ /L	1.37 (1.0–1.9)	1.45 (1.04–2.00)	1.35 (0.99–1.79)	0.089	1.29 (0.90–1.87)	1.43 (1.05–1.91)	0.067
Platelet count, ×10 ⁹ /L	186.5 (150.5–231.5)	193.0 (163.0–241.0)	176.0 (142.0–228.0)	0.021	175.5 (137.0–219.0)	188.0 (159.0–238.5)	0.033
APTT, s	39.15 (36.1–42.1)	38.1 (35.9–40.8)	39.9 (36.5–43.2)	0.003	39.6 (36.4–43.0)	39.0 (35.9–41.2)	0.141
D-dimer, mg/L	1090 (710–1570)	990 (640–1400)	1150 (740–1640)	0.014	1240 (780–1990)	1050 (660–1460)	0.006
Albumin, g/L	40.05 (36.65–42.45)	40.4 (37.4–42.9)	39.3 (36.0–42.2)	0.068	37.4 (34.7–40.5)	40.6 (37.7–43.2)	<0.001
ALT, U/L	20 (14–31.3)	17.70 (13.00–27.76)	21.60 (15.20–34.95)	0.024	22.65 (16.00–37.55)	19.60 (13.60–27.76)	0.014
AST, U/L	19.7 (16.4–27.6)	18.25 (15.10–24.00)	20.90 (17.30–29.00)	0.002	25.80 (18.40–33.30)	18.45 (15.85–23.15)	<0.001
Total bilirubin, mmol/L	9.58 (6.7–13.75)	10.22 (6.65–13.82)	9.26 (6.97–13.56)	0.908	10.14 (7.37–14.05)	9.39 (6.65–13.54)	0.364
Potassium, mmol/L	3.6 (3.3–3.89)	3.60 (3.34–3.80)	3.60 (3.30–3.90)	0.884	3.5 (3.2–3.9)	3.6 (3.4–3.8)	0.206
Sodium, mmol/L	140 (138–142)	141.0 (139.0–142.0)	139.0 (138.0–141.0)	<0.001	139.0 (136.3–141.0)	140.0 (139.0–142.0)	0.007
Creatinine, μmol/L	60.4 (49–76.6)	57.50 (46.80–74.60)	61.90 (51.55–77.45)	0.055	60.365 (48.55–76.70)	60.40 (50.80–75.70)	0.576
CK, U/L	67 (44–104)	66.5 (45.0–92.0)	67.0 (44.0–117.0)	0.218	64.5 (44.0–128.0)	68.0 (45.0–101.1)	0.719
LDH, U/L	188 (152–235)	173.0 (144.0–223.0)	198.0 (157.0–249.0)	0.005	214.5 (158.0–292.0)	179.0 (149.0–224.0)	0.001
Procalcitonin, ng/mL	0.098 (0.0374–30)	0.10 (0.04–30.00)	0.09 (0.04–28.90)	0.446	0.13 (0.04–36.40)	0.07 (0.04–26.80)	0.129
CRP, mg/L	5 (5–45.5)	5.0 (5.0–17.0)	7.0 (5.0–57.0)	<0.001	17.0 (5.0–78.0)	5.0 (5.0–31.5)	<0.001
On serial assessment							
Nadir WBC, ×10 ⁹ /L	4.48 (3.52–5.42)	4.36 (3.48–5.44)	4.49 (3.57–5.35)	0.941	4.49 (3.36–5.60)	4.47 (3.67–5.34)	0.682
Nadir neutrophil count, ×10 ⁹ /L	2.36 (1.78–3.09)	2.36 (1.71–3.03)	2.33 (1.90–3.12)	0.407	2.52 (1.83–3.41)	2.33 (1.78–2.99)	0.180
Nadir lymphocyte count, ×10 ⁹ /L	1.27 (0.92–1.67)	1.37 (1.02–1.93)	1.14 (0.87–1.56)	<0.001	1.10 (0.81–1.58)	1.33 (0.99–1.72)	0.002
Peak neutrophil count, ×10 ⁹ /L	3.70 (2.90–5.05)	3.51 (2.89–4.46)	4.00 (3.06–5.64)	0.003	4.23 (3.12–6.55)	3.56 (2.82–4.60)	0.001
Peak monocytes, ×10 ⁹ /L	0.44 (0.37–0.55)	0.41 (0.35–0.49)	0.46 (0.38–0.57)	0.001	0.44 (0.38–0.56)	0.44 (0.36–0.54)	0.406
Peak D-dimer, 500 mg/L	1220 (820–1850)	1090 (720–1460)	1480 (1010–1990)	<0.001	1460 (910–2270)	1180 (780–1740)	0.025
Peak ALT, U/L	28.15 (17.30–44.00)	23.0 (16.0–39.0)	35.0 (21.7–56.3)	<0.001	38.70 (21.60–70.90)	25.55 (16.45–39.40)	<0.001
Peak AST, U/L	22.55 (17.90–32.25)	20.1 (16.6–27.4)	25.0 (19.1–37.8)	<0.001	29.45 (20.45–52.35)	20.90 (17.10–26.85)	<0.001
Peak creatinine, μmol/L	68.5 (56.6–82.1)	65.40 (52.45–79.70)	70.30 (58.45–82.35)	0.034	70.20 (55.60–81.90)	67.90 (57.50–82.70)	0.703
Peak CK, U/L	70.5 (49.0–106.0)	67.0 (47.0–93.0)	74.5 (51.5–120.5)	0.039	69.0 (47.0–129.0)	71.5 (51.0–103.5)	0.566
Peak LDH, U/L	210 (166–279)	188 (153–239)	223 (178–298)	<0.001	236.5 (185.0–324.0)	198.0 (158.0–241.0)	<0.001
Peak CRP, mg/L	5.00 (5.00–33.24)	5.00 (5.00–17.70)	20.49 (5.00–40.71)	<0.001	22.47 (5.00–50.01)	5.00 (5.00–25.15)	<0.001

WBC, white blood cell count; PT, prothrombin time; APTT, activated partial thromboplastin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase; CRP, C-reactive protein.

Table S2 Clinical outcomes and adverse complications during hospitalization

Variables	No. (%)	Time from admission to clinical outcomes or adverse complications, days
Clinical outcomes		
Discharge	280 (98.25)	18 (13–24)
ICU admission	20 (7.02)	0 (0–4.5)
Death	1 (0.35)	33
Adverse complications		
Any complication	90 (31.58)	13 (8–21)
Electrolyte disturbances	43 (15.09)	5 (1–8)
Liver damage	34 (11.93)	8 (3–13)
Secondary infection	15 (5.26)	5 (2–8)
Acute kidney injury	11 (3.86)	7 (2–10)
Respiratory failure	9 (3.16)	7 (5–10)
Myocardial damage	9 (3.16)	5 (1–13)
Arrhythmia / Atrial fibrillation	9 (3.16)	8 (5–10)
MODS	4 (1.40)	11 (3–26)
ARDS	3 (1.05)	17 (16–34)
VAP	3 (1.05)	34 (31–37)
Shock	3 (1.05)	17 (12–19)
Gastrointestinal hemorrhage	3 (1.05)	1 (1–10)
Acute kidney failure	2 (0.70)	16.5 (15–18)
Depression	2 (0.70)	12.5 (0–25)
DIC	1 (0.35)	26 (26–26)
Pulmonary embolism	1 (0.35)	18 (18–18)
Heart failure	1 (0.35)	12 (12–12)

Data are presented as the median (interquartile range) or n (%). MODS, multiple organ dysfunction syndrome; ARDS, acute respiratory distress syndrome; VAP, ventilator associated pneumonia; DIC, disseminated intravascular coagulation.

Table S3 Symptoms during hospitalization

Symptoms	No. (%)
Fever	221 (77.5)
Dry cough	218 (76.5)
Expectoration	130 (45.6)
Anorexia	118 (41.4)
Dyspnea	99 (34.7)
Fatigue	79 (27.7)
Chills	73 (25.6)
Nausea	72 (25.3)
Myalgia	39 (13.7)
Headache	38 (13.3)
Pharyngalgia	38 (13.3)
Vomiting	38 (13.3)
Dizziness	36 (12.6)
Diarrhea	35 (12.3)
Abdominal pain	18 (6.3)